Cysteamine Spike Bond Cleavage for SARS-CoV-2 Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current containment strategies for COVID-19 are inadequate, particularly in overwhelmed hospitals, with limited ICU resources and high mortality rates, necessitating effective mitigation and prevention methods for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections.
Innovation Solution
Administration of cysteamine or its derivatives to target disulfide bonds in spike proteins of SARS-CoV-2 and other coronaviruses, reducing their ability to infect cells through topical administration to aerodigestive locations, including nasal, bronchial, and systemic routes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If containment strategies are implemented in overwhelmed hospitals, then resource utilization is improved, but mortality rate increases due to limited ICU resources
Solution Approach 1:
The patent applies preliminary action by administering cysteamine to patients before they require ICU admission or during early stages of infection. This preventive treatment aims to reduce viral load and prevent disease progression to severe stages, thereby reducing the burden on ICU resources while improving patient outcomes and reducing mortality rates
2Reliability
If cysteamine is administered to cleave disulfide bonds in spike proteins, then viral infection ability is reduced, but potential toxicity and side effects may occur
Solution Approach 1:
The patent applies parameter changes by optimizing the dosage, administration frequency, and duration of cysteamine treatment. By carefully controlling these parameters, the patent seeks to achieve effective cleavage of disulfide bonds in viral spike proteins while maintaining plasma cysteamine levels within a safe range to minimize toxicity and side effects
Solution Approach 2:
The patent uses cysteamine as an intermediary substance that selectively targets and cleaves disulfide bonds in viral proteins without permanently damaging host cell proteins. The transient nature of cysteamine action and its ability to be metabolized and eliminated from the body allows it to serve as a safe intermediary therapeutic agent
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Cysteamine effectively inhibits viral replication and infection by cleaving disulfide bonds in spike proteins, providing treatment and prevention of SARS-CoV-2 infections, including variants, with minimal toxicity and side effects, and reducing the spread of the virus.
Implementation Method 1
Coronaviruses may have proteins that are employed during infection, e.g., spike proteins, having disulfide bonds that can be cleaved by the cysteamine active agent
Data Source
AI summary
Provided herein are methods for the treatment, mitigation, and prevention of viral infections (e.g., coronavirus infections (e.g., severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), etc.), etc.) and diseases (e.g., Coronavirus disease 2019 (COVID-19)) associated therewith by the administration of cysteamine or derivatives thereof to a subject.